ArticleFrontiers in medicine2026
Eculizumab for ATCR-associated
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to explore the efficacy of eculizumab in the treatment of newly developed thrombotic microangiopathy (TMA) associated with acute T-cell-mediated rejection (ATCR) in patients with type 2 diabetes after kidney transplantation. Methods: New-onset thrombotic microangiopathy (TMA) after kidney transplantation is a relatively rare but serious complication that is clinically challenging to manage and requires timely intervention to prevent graft dysfunction or early graft loss. Currently, there is no consensus in clinical practice regarding the diagnosis, optimal treatment strategies, or preventive measures for post-transplant new-onset TMA. This article provides a retrospective analysis of the first case in China successfully treated with eculizumab for Patient: The patient was a 59-year-old male who underwent cadaveric donor kidney transplantation on July 31, 2024. The surgery was successful, and postoperative recovery was good. He was followed up in the outpatient department every week. On September 15, 2024, the patient experienced acute pain and swelling in the right lower abdomen, and his 24-h urine output decreased to 1,200 mL. After admission, biopsy of the transplanted kidney was performed, and severe thrombotic microangiopathy (TMA) was diagnosed. After pathological diagnosis, eculizumab was administered for 3 months (900 mg/time in the first four weeks, once a week; 1,200 mg/time from the fifth week to the 12th week, once a week). Results: After eculizumab treatment, the patient's clinical symptoms improved significantly. Laboratory indicators, such as platelet count, lactate dehydrogenase (LDH), and serum creatinine (SCr) gradually returned to normal. During the 9-month follow-up after the last dose, the SCr level remained stable at 180 μmol/L, with no recurrence of thrombotic microangiopathy (TMA) and no signs of proteinuria were observed. Conclusion: Eculizumab is effective in treating new-onset ATCR-related TMA in patients with type 2 diabetes after kidney transplantation, and treatment should be initiated immediately after diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.